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Abstract
Estradiol may fulfill a plethora of functions in neurons, in which much of its activity is associated with its capacity to directly
bind and dimerize estrogen receptors. This hormone-protein complex can either bind directly to estrogen response elements
(ERE’s) in gene promoters, or it may act as a cofactor at non-ERE sites interacting with other DNA-binding elements such as AP-
1 or c-Jun. Many of the neuroprotective effects described for estrogen have been associated with this mode of action.
However, recent evidence suggests that in addition to these ‘‘genomic effects’’, estrogen may also act as a more general
‘‘trophic factor’’ triggering cytoplasmic signals and extending the potential activity of this hormone. We demonstrated that
estrogen receptor alpha associates with b-catenin and glycogen synthase kinase 3 in the brain and in neurons, which has since
been confirmed by others. Here, we show that the action of estradiol activates b-catenin transcription in neuroblastoma cells
and in primary cortical neurons. This activation is time and concentration-dependent, and it may be abolished by the estrogen
receptor antagonist ICI 182780. The transcriptional activation of b-catenin is dependent on lymphoid enhancer binding factor-
1 (LEF-1) and a truncated-mutant of LEF-1 almost completely blocks estradiol TCF-mediated transcription. Transcription of a
TCF-reporter in a transgenic mouse model is enhanced by estradiol in a similar fashion to that produced by Wnt3a. In addition,
activation of a luciferase reporter driven by the engrailed promoter with three LEF-1 repeats was mediated by estradiol. We
established a cell line that constitutively expresses a dominant-negative LEF-1 and it was used in a gene expression microarray
analysis. In this way, genes that respond to estradiol or Wnt3a, sensitive to LEF-1, could be identified and validated. Together,
these data demonstrate the existence of a new signaling pathway controlled by estradiol in neurons. This pathway shares
some elements of the insulin-like growth factor-1/Insulin and Wnt signaling pathways, however, our data strongly suggest that
it is different from that of both these ligands. These findings may reveal a set of new physiological roles for estrogens, at least
in the Central Nervous System (CNS).
Citation: Varea O, Garrido JJ, Dopazo A, Mendez P, Garcia-Segura LM, et al. (2009) Estradiol Activates b-Catenin Dependent Transcription in Neurons. PLoS
ONE 4(4): e5153. doi:10.1371/journal.pone.0005153
Editor: Lin Mei, Medical College of Georgia, United States of America
Received October 29, 2008; Accepted February 17, 2009; Published April 10, 2009
Copyright:  2009 Varea et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from CIBERNED (which was an initiative of the ISCIII), Plan Nacional DGCYT, SAF2006-12782-C03-01 and by an
Institutional grant from the Fundacion Areces. OV was supported by MEC fellowship and CIBERNED contract. PM was supported by MEC fellowship. The funders
had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: fwandosell@cbm.uam.es
Introduction
Estrogens fulfill a wide range of functions during development
and differentiation in mammals of both sexes. In addition to these
functions, they are also thought to play an important role in
neuroprotection [1–3]. The actions of estrogens have been
classified as either ‘‘genomic actions’’ or ‘‘non-genomic, rapid
actions’’. The genomic actions are based on the capacity of the
estrogen receptors (ERs) to bind to co-activators or co-repressors
in order to enhance or inhibit the transcription of target genes, and
it has been reported in many cell types (reviewed in [4]). This
activity involves the dimerization of two receptor molecules
mediated by the presence of the hormone and the generation of
a macromolecular complex with co-regulators (reviewed in [5]).
The ERs belong to the nuclear receptor superfamily and two
receptors, alpha and beta, have been identified (NR3A1 and
NR3A2, according to the nomenclature of the NRN Committee
[6]. The structure of both receptors is similar containing a highly
homologous DNA-binding region (95%) and a hormone binding
region with weaker homology (69%), whereas the carboxy and
amino-terminal regions are the most divergent regions (58%
homology, reviewed in [7]). Apart from this genomic action,
estrogen can trigger rapid ‘‘non-genomic signaling’’ associated
with the activation of second messengers. Among these, the
activation of the mitogen activated protein kinase (MAPK) [8],
protein kinase C (PKC) [9] and phosphoinositide 3-kinase (PI3K)
[10] signaling pathways has been described. Indeed, cooperation
with insulin-like growth factor-1 (IGF-1) has been demonstrated
and ERa has been reported to associate with p85, the regulatory
subunit of PI3K [11–12]. Furthermore, estrogens may also act in a
ligand-independent manner [13] and they may exert certain
antioxidant effects that are independent of their receptors.
We recently demonstrated that ERa is linked to PI3K
associated ‘‘cytoplasmic signaling’’ in the brain and in primary
neurons, where estradiol can induce the immediate activation of
Akt/PKB and the subsequent inhibition of glycogen synthase
PLoS ONE | www.plosone.org 1 April 2009 | Volume 4 | Issue 4 | e5153
kinase 3 (GSK3). On the light of the important role proposed for
GSK3 in neuronal survival [14] and in neuropathologies such as
amyloid neurotoxicity [15], the role of this new estradiol signaling
pathway merits further analysis.
We also identified novel complexes in which ERa, GSK3 and
b-catenin were associated, demonstrating that the action of
estradiol transiently stabilized b-catenin, which is disassociated
from the complex with ERa [12]. The stabilization of b-catenin
has been related with different functions of this protein. In
addition to act in cell-cell adhesion, b-catenin also serves as a co-
transcriptional regulator, modulating the functions of the T cell
factor (TCF)/ lymphoid enhancer binding factor (LEF) proteins
that are closely associated with Wnt signaling (reviewed in [16–
19]). Hence, the stabilization of b-catenin by estradiol may also
have effects on gene transcription.
In this study we have assessed whether the b-catenin, stabilized
by estradiol in neurons, may exert a significant effect at the
transcriptional level. We show that the stabilization of b-catenin by
estradiol is correlated with the inhibition of GSK3 in neuronal-like
cells (N2a-m), as well as in cortical neurons. Indeed, estradiol
increased TCF/LEF-1 transcription in a dose-dependent manner.
This increase in transcription was partially prevented by the
addition of an estradiol antagonist and was mimicked by an alpha
and beta specific-agonist. In neuronal cells, estradiol induced the
formation of a TCF-DNA complex that was impaired by the
presence of antibodies against LEF-1. Moreover, in cortical
neurons from a TCF/LEF-1–bgal transgenic mouse, b-galactosi-
dase activity was up-regulated by the action of estradiol. Finally, in
a LEF-1 mutant cell line, we identified some genes that were
differentially regulated by estradiol.
Together, all these data demonstrate that in addition to its
nuclear action mediated through the ER, estradiol triggers a signal
that recruits b-catenin and LEF-1 and that may be responsible for
more wide-ranging actions of this hormone, at least in neurons.
Results
Estradiol transiently regulates the phosphorylation of
GSK3 and the amount of b-catenin in N2a-m neuronal
cells and cortical neurons
We recently demonstrated that estradiol inhibit GSK3 and
stabilize b-catenin in the hippocampus and in hippocampal
neurons. To further analyze this phenomenon, it was necessary to
transfect neuronal cells. We first examined whether neuroblastoma
cells behave like primary neurons concerning this estrogenic
action. We found that N2a-m cells, a clone derived from NB2a
(ATCC: CCL 131) and that has been maintained for several years
in our laboratory, responded to estradiol in a similar manner as
primary neurons, as demonstrated below.
The effect of estradiol on this cell line was examined and we
initially determined whether N2a-m cells expressed both a and b
estrogen receptors when maintained in serum–free medium
(Supplementary Figure S1). When N2a-m cells were exposed to
estradiol, ERa-immunoreactivity became more concentrated in
the nucleus in a time and dose dependent manner (Supplementary
Figure S1). Thus, since these cells respond to estradiol and can be
efficiently transfected, we analyzed whether exposure to estradiol
could modify GSK3b-PSer using primary cortical neurons as a
reference in parallel. Immunoreactivity against GSK3b-PSer was
increased in N2a-m cells exposed to estradiol, reaching a
maximum (561 fold, n = 4) 60–90 minutes after the addition of
the hormone (Figure 1A). A similar time-course of GSK3b-PSer
immunoreactivity was observed in cortical primary neurons
(Figure 1C), reaching a maximum increase (2.260.5 fold; n= 3)
90 minutes after exposure to the hormone. The increase in serine
phosphorylation of GSK3b was dose-dependent and was maximal
in the range of 100 to 200 nM (2.560.5 fold; n= 3, Figure 1A).
The second important element in our analysis is b-catenin, as
demonstrated in hippocampal neurons [12]. Thus, we determined
whether inhibition of GSK3 was correlated with the stabilization
of b-catenin in cell extracts from N2a-m and cortical neurons
treated with estradiol (100 nM). The total amount of b-catenin
increased in both N2a-m cells (3.560.5 fold; n= 3) (Figure 1A) and
cortical neurons (2.260.3 folds, n = 3) (Figure 1C), with a time-
course similar to that of the changes in GSK3-PSer (Figure 1 A
and B). The increase in the stabilization of b-catenin by estradiol
was prevented by ICI 182780, a specific ER receptor antagonist
(ICI/estradiol ratio was maintained 1006) (Figure 1B).
A complex of ER a and b-catenin was recently detected in the
hippocampus of female ovariectomized rats [12]. We assessed
whether a similar complex was present in extracts from N2a-m
cells. Our data showed that b-catenin was detected in complexes
immunoprecipitated with antibodies against ERa or ERb
(Figure 2). Similarly, both GSK3a and b were detected in these
complexes, although there was less GSK3 recovered when
antibodies against ERa were used. As a positive control in these
experiments, material was immunopreciptated with an antibody
against Adenomatous Polyposis Coli protein (APC) and in these
latter experiments, mostly GSK3b was detected (Figure 2).
Estradiol increase the association of b-catenin to the
neuronal membrane fraction
Given that b-catenin may fulfill two distinct cellular functions,
as an adhesion molecule or as co-transcription factor. Two
different pools have been described associated with different
functions [16,20]. Thus, we determined whether estradiol-
mediated stabilization augmented either of the putative b-catenin
pools. Membrane and nuclear fractions were obtained from
cultured neurons exposed to the hormone for 30 and 60 minutes.
Interestingly, the amount of b-catenin detected in the membrane
fraction was increased at 30 and 60 minutes after exposure to
estradiol whereas the nuclear fraction was almost unaffected
(Supplementary Figure S2).
Estradiol activates TCF-mediated transcription
Even though accumulation of b-catenin in the cell nucleus could
not be perceived at the biochemical level, we assessed whether
estradiol might induce b-catenin mediated transcriptional activa-
tion. For this purpose we transfected N2a-m cells with a TCF-
luciferase reporter (TOPFlash) in combination with an EGFP
reporter. When estradiol (100 nM) was added after cell transfec-
tion, luciferase activity increased 2464 fold (n = 4, Figure 3D),
reaching a maximum 60–90 minutes after hormonal exposure
(Figure 3A). The estradiol-induced increase in luciferase activity
was time and concentration-dependent (Figure 3A–B). Moreover,
the transcriptional activity depended on ERs since it was
drastically reduced when the ER antagonist ICI 182780 was
applied in conjunction with estradiol (Figure 3C). In parallel, when
we transfected N2a-m cells with a mutated form of the TCF
reporter (FOPFlash) we were unable to detect luciferase activity
(Figure 3C).
To determine whether this transcriptional activation was
associated with ER a or ER b, we used two specific agonists of
either the a or b receptor isoforms. Both 4,49,40-(propyl-[(1)H]-
pyrazole-1,3,5-triyl) trisphenol (PPT, a-selective) and 2,3-bis (4-
hydroxyphenyl) propionitrile (DPN (b-selective) agonists increased
transcriptional activity in N2a-m cells, although the activity
mediated by PPT was more prominent that that mediated by
Estradiol Modulates b-Catenin
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DPN, suggesting that ER a is more effectively coupled to this
novel pathway (Figure 3D). As a positive control of this TCF-
reporter, we took advantage of the fact that this neuronal cell
responds to some Wnt proteins and thus, b-catenin stabilization
was detected when N2a-m cells were exposed to Wnt3a
(Supplementary Figure S3). When we exposed cells to Wnt3a
Figure 1. Treatment of estradiol increases Ser9,21-GSK3 phosphorylation and b-catenin accumulation in neuronal cells. (A)-
Neuroblastoma N2a-m were treated with different doses of estradiol and for different times (20–120 min with 10–500 nM) and the maximum
increase in GSK3b-PSer9 was observed when they were treated for 60 min with 100–200 nM estradiol. (B)- Stabilization of b-catenin. N2a-m cells
treated with estradiol showed a clear increase in b-catenin that could be prevented by prior exposure to ICI 182780 (used 1006 concentrated in
comparison to estradiol), 60 minutes before estradiol treatment (lower panel). (C)-Cortical Primary Neurons (2DIV) were treated with estradiol
(100 nM) and the maximum increase in GSK3b-PSer9 and the subsequent stabilization of b-catenin was clearly detected 60–90 min after the onset of
exposure. In all cases diagram shows the mean normalized densitometry values and the corresponding standard deviations from at least three
independent experiments. Asterisks indicate statistical significance (Student’s t-test) ** (P#0.05), * (P#0.01). The single * or ** compares data to
control whereas the bar between different points shows statistical differences between experimental values.
doi:10.1371/journal.pone.0005153.g001
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after TOPFlash transfection, the transcriptional activation ob-
tained in response to Wnt3a was similar to that obtained after
estradiol treatment (Supplementary Figure S3).
The expression of a TCF-b-galactosidase reporter, as well
as an engrailed-1 promoter luciferase reporter, is
modulated by estradiol in primary neurons
To determine whether estradiol can regulate the expression of a
reporter controlled by TCF in primary neurons, we used two
complementary approaches. First, we transfected TOPFlash or
FOPFlash into primary neurons (Figure 4A) and after TOPFlash
transfection, we detected an increase in luciferase activity (4.861.2
folds; n = 3) in the presence of estradiol (100 nM), which was not
induced after FOPFlash transfection (Figure 4A). High concen-
trations of insulin (ITS supplements) also produced a 10-fold
increase in these cells as a positive control (Figure 4A). In a second
approach, we obtained primary cultures of cortical neurons from
TCF-bgal transgenic mice, a colony designed to analyze the
activation of the Wnt pathway in vivo [21]. We detected b-
galactosidase expression in almost all cortical neurons of TCF-bgal
transgenic mice (Figure 4B) and thus, we analyzed the amount of
b-galactosidase after exposure to either estradiol or Wnt3a. Both
estradiol and Wnt3a produced a similar moderate increase in b-
galactosidase, assessed in western blots (Figure 4B). This finding
was confirmed by quantitative RT-PCR in parallel experiments.
Hence, in total RNA obtained from cultured cortical neurons, a
similar increase in the expression of the LacZ-transgene was
detected by RealTime RT-PCR after exposure to Wnt3a or
estradiol when normalized to actin mRNA expression (Figure 4C).
As a complementary alternative we try to analyze whether an
endogenous promoter may be regulated by estradiol in a similar
fashion as Wnt3a. For that purpose we used a construct containing
a 2.8 Kb region of the Engrailed-1 promoter that has three LEF-1
sites situated upstream of a luciferase gene pENP1Luc [22] (see
scheme in Figure 5A). Again luciferase expression was clearly
driven by estradiol, although at identical amounts of cDNA the
response of TOPFlash was more potent (Figure 5B).
Does estradiol use a b-catenin/TCF transcription system
similar to that used by Wnt?
The mechanism by which Wnt modulates b-catenin-mediated
transcription is sensitive to the phosphorylation of b-catenin as
well as to b-catenin/TCF binding (reviewed in [17]). Thus, when
we transfected N2a-m cells with different amounts of a
constitutively active mutant of b-catenin (S33Y), the transcrip-
tional activity in extracts of these cells was almost maximal and it
was virtually insensitive to the addition of estradiol (15–20%),
when compared with 5–12 folds induction (control or mock-
transfected cells versus estradiol) (Figure 6A versus Figure 3B–C). In
all these experiments, the total amount of b-catenin after
transfection and treatment was controlled to ensure that it did
not influence the results (Figure 6B). Hence, these data strongly
suggested that estradiol-mediated transcription requires the
formation of a b-catenin/TCF complex. Indeed, when a version
of LEF-1 that is truncated in the b-catenin binding region
(D56LEF-1) [23] was transiently transfected into N2a-m neuro-
blastoma cells in combination with TOPFlash, estradiol did not
drive luciferase expression (Figure 6C), whereas N2a-m-mock
transfected cells responded to estradiol as previously shown.
Similarly, when we transiently transfected into N2a-m neuro-
blastoma cells with D56LEF-1 in combination with pENP1 Luc,
the luciferase expression estradiol-mediated was severely reduced by
the expression of LEF1-mutant (Figure 6D).
Are b-catenin/TCF-DNA complexes activated by
estradiol?
To determine whether the estradiol-mediated transcriptional
activation detected in our study relies on similar complexes to
those described for Wnt, we assayed the DNA-protein complexes
with TCF-binding sequence in nuclear extracts from N2a-m cells
(EMSA assay). We detected a DNA-protein complex that was more
evident after estradiol or Wnt3a treatment (Figure 7). Moreover,
the formation of this complex was impaired by pre-incubation
with the ER antagonist ICI 182780 and the detection of the
complex could be competed with unlabelled TCF-oligonucleotide
but not by a mutant TCF oligonucleotide (Figure 7 A).
Four members of TCF family have been described (TCF1, LEF-
1, TCF3, and TCF4), the first three of which are found in
neuronal tissues [24]. To determine which of these may participate
in the TCF/DNA complex described in our system, we pre-
incubated the nuclear extracts with specific antibodies against
TCF1, LEF-1 or TCF3, as well as with antibodies against ERa or
irrelevant IgGs. The antibody against LEF-1 abolished the
formation of the DNA-protein complex while the antibodies
against TCF1, TCF3 and ERa did not appreciably modify the
DNA-protein complex (Figure 7B and supplementary Figure S4).
Are the genes regulated by estradiol/b-Catenin/LEF-1
similar to those regulated by Wnt/b-Catenin/TCFs?
Together, the data obtained so far suggested that estradiol
might activate a b-Catenin/LEF-1 complex that is similar to that
activated by Wnt in other systems. Thus, to shed further light on
Figure 2. Estrogen receptors form a complex with b-catenin
and GSK3 in N2a-m cells. ERa and ERb were immunoprecipitated
from N2a-m cells, and similar endogenous protein complexes were
observed with both antibodies. Immunoprecipitation with an anti-APC
antibody is shown as an internal control of a b-catenin interacting
protein. Both GSK3 isoforms were detected in the immunocomplex
recovered with ERa or ERb antibodies, whereas GSK3b is the major
isoform recovered with APC antibodies, used as a positive control. The
immunoprecipitation also shows a fraction of b-catenin associated with
both ER isoforms. IgG’s represent the IP using irrelevant IgGs as a
negative control.
doi:10.1371/journal.pone.0005153.g002
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this new molecular mechanisms, we took advantage of the fact that
the D56LEF-1 construct may act as a dominant-negative construct
and we generated N2a-m cells stably transfected with D56LEF-1
(Figure 8A). This cell line presented a more differentiated
morphology, with bipolar extension of two processes (Figure 8A).
As an internal control, we analyzed the presence of the
D56LEF-1 as well as the endogenous LEF-1. The expression of
D56LEF-1 in this cell line was not drastically impaired, and it was
maintained at an mRNA and protein ratio of at least 1:1 when
compared with LEF-1, in a cell line mock-transfected with the
empty pcDNA3.1 vector (Figure 8B and C). The dominant-
negative activity of the LEF-1 mutant was observed when the cell
line was transiently transfected with TOPFlash. The expression of
luciferase was still blocked when the cells were incubated with
estradiol, as described previously (Figure 8C). Even though,
estrogen receptor and b-catenin may be detected in the nuclear
fraction of these transfected cells (Figure 8C).
Subsequently, stably transfected N2a-m cells were utilized to
obtain the total RNA, either from empty pcDNA3/N2a-m (group
A) or D56LEF-1/N2a-m (group B). In both cases, cells were
Figure 3. Estradiol augments TCF/LEF-dependent transcription in N2a-m cells. N2a-m cells were transfected with the TOPFlash or FOPFlash
reporter plasmid with EGFP-pCDNA3, and the cells were then treated with estradiol and other test compounds for the different times and at the
different concentrations indicated. (A–B), Soluble extracts from estradiol treated cells were obtained and luciferase activity was measure as indicated
in the Methods. The normalized data were expressed in relative light units (RLU) compared to the control solvent, and the response was maximal at
60 min using 100 nM. (C).The effect of estradiol can be prevented by prior exposure to the ER antagonist ICI 182780 10 mM for 2 hr. (D), Specific
agonists of each estrogen receptor (PPT: ERa agonist, and DPN: ERb agonist, at two concentrations, 5 and 10 nM) also induced TCF/LEF-mediated
transcription although PPT was more efficient than DPN. The graphs show the normalized luciferase activity from at least three independent
experiments. The P value from the Student’s t-test was * (P#0.05), ** (P#0.01). The single * or ** compares data to control whereas the bar between
different points shows statistical differences between them.
doi:10.1371/journal.pone.0005153.g003
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Figure 4. Estradiol increase TCF/LEF-dependent transcription in cortical neurons. (A)-Cortical neurons from E18 embryos were
nucleofected with TOPFlash or FOPFlash reporter plasmids and luciferase activity was analyzed after 2DIV. Estradiol treatment (60 min, 100 nM)
selectively increased transcription from the TOPFlash reporter plasmid compared to FOPFlash, which shows no activity. Insulin treatment (5 mg/ml)
was used as a control of induction. (B–C)- Expression of the LacZ gene in response to estradiol in transgenic mice. The scheme represents the lacZ
transgene under the control of three consensus TCF/LEF-binding motifs upstream of the c-fos promoter, as described in Materials and Methods. (B)-
Upper panel. Total extracts of cortical neurons (2DIV) were obtained from a TCF/LEF-lacZ transgenic mouse (see Materials and Methods) and the b-
Estradiol Modulates b-Catenin
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treated with estradiol or Wnt3a for 60 minutes and then total
RNA was purified. Gene expression from the two stable cell types
(A and B) was then analyzed using the Applied Biosystems Mouse
Genome Survey Microarray (Applied Biosystems).
Genes were normalized with respect to control untreated cells,
and divided in different groups. From these groups, we only
consider those with differences when compared group A versus
group B, for each treatment. From these we selected those with a
log2R higher or lower than 1, being 102 genes upregulated and
121 genes downregulated by estradiol; and 137 genes upregulated
and 166 genes downregulated by Wnt3a. Table 1 described the
list of the annotated genes present in the protein bank with the Ref
Seq and the Gene Name. In contrast, the genes modified only after
estradiol treatment or only after Wnt3a treatment that presented
no significant differences between A and B were discarded.
Initially, for the confirmation of the putative deferential response
of both cells (A vs B) we selected two genes presented in both
arrays that were modified by Wnt as well as by estradiol
(Plasminogen and LEF-1). A final validation was performed using
specific antibodies against the selected proteins (Figure 9 and 8C).
Thus, plasminogen expression in D56LEF-1 cells was 2.5 fold
higher, although these initial differences were not considerably
augmented by treatment with Wnt or estradiol. Similarly, the
endogenous LEF-1 was reduced by the presence of the mutant
version of this protein (Figure 8). In addition we selected some
genes, previously reported by other laboratories as Wnt targets ,
such as TCF’s, Cyclin D, Myc, MMP’s (for updated, please check,
The Wnt Homepage, at http://www.stanford.edu/,rnusse/pathways/
targets.html).
As shown in figure 9A, the log2 R of some of these genes was
low, and certainly, the protein expression showed no differences.
Considering that the low level of detection may be related with the
short exposure time (60 minutes), we extended the treatment to
confirm the differential regulation of some genes mediated by
Figure 5. The engrailed 1-luciferase construct responds to estradiol. The scheme represents the structure of the 2.8 kB of construct
containing the proximal region of endogenous engrailed 1 promoter bind to luciferase reporter. N2a-m cells were transfected with the pENP1-
luciferase reporter plasmid (250, 200 and 750 ng) (represented as 0.25, 0.5, 0.75), which contains three LEF-1 sites (see upper panel). The Lower
panel shows a comparison of the induction of TOPFlash (750 ng) and pENP-luc in this cell line. Although basal levels of luciferase activity are lower in
the pENP1-luc reporter plasmid, estradiol induces this activity to 3-fold that of the control levels, as shown in the right panel. The graph in B shows
the normalized luciferase activity from at least three independent experiments. The P value from the Student’s t-test was ** (P#0.01) when compared
with control data.
doi:10.1371/journal.pone.0005153.g005
galactosidase (b-gal) expression was assessed in western blots after estradiol treatment (100–200 nM) for 3 h. Wnt3a (20 ng/ml) was used as a control
of TCF-mediated induction. A slight increase in b-gal protein was observed after exposure to estradiol, as with recombinant Wnt3a protein. (B), Lower
panel. Basal expression of b-galactosidase in neurons from transgenic mice was assessed by immunocytochemistry using specific antibodies against b
galactosidase (green) and Phalloidin-labelled with Alexas 549. (C), Alternatively, after treatment with estradiol or Wnt3a, total Lac Z expression was
quantified by RT-PCR using specific b-gal oligonucleotides and using actin (a housekeeping gene) as an internal standard (see Methods). The
amplification of both genes was analyzed on agarose gels and the graph represents the normalized data obtained from the Lightcycler analysis. Both
treatments clearly increase transcriptional activity when compared to controls.
doi:10.1371/journal.pone.0005153.g004
Estradiol Modulates b-Catenin
PLoS ONE | www.plosone.org 7 April 2009 | Volume 4 | Issue 4 | e5153
D56LEF-1. Accordingly, we treated the cell lines with estradiol or
Wnt3a over a period of 24 h to allow for the accumulation of the
protein. Soluble fraction, or nuclear fractions, or conditioned
medium was obtained from treated cells and we analyzed the
genes identified as differentially expressed in the microarray (when
antibodies were available) as well as some genes known to be
regulated by Wnt, such as E-cadherin, b-catenin or cyclin D.
Our data confirmed some of the variations in the genes
described. Interestingly, MMP-2 secretion was most prominent in
Wnt-treated cells whereas the proactive form appeared to be
Figure 6. Interaction of b-catenin/LEF-1 mediates the transcriptional capacity of estradiol. (A)-b-catenin/TCF estradiol-mediated
transcription depends on the phosphorylation of b-catenin. N2a-m cells were transfected with different amounts of the S33Y-bcatenin (S33Y-bcat)
expression plasmid as indicated (250 or 500 ng). (B)-b-catenin levels in total extracts from cells transfected with S33Y-bcat or the empty cDNA3.1
plasmid, representative of the analysis of lanes (0.5+); and (0.52) in A. Under the high levels of S33Y-bcat expression estradiol was virtually unable to
further induce reporter expression. No statistical differences are founded between the bars data from different experiments. (C)-Interaction of b-
catenin with TCFs is essential for estradiol to induce gene transcription through TCF sites. Endogenous LEF-1 protein levels remain unchanged after
estradiol treatment for 60–90 min, as seen with the anti-N terminal LEF-1 antibody. Expression of the D56LEF-1 protein was detected in western blots
after transfection of increasing amounts of plasmid (400 or 600 ng) using an antibody against the HMG box region of LEF-1. The overexpression of a
LEF-1 mutant construct (D56LEF-1) prevents estradiol from inducing expression from the TOPFlash reporter plasmid when compared with mock-
transfected cells. (D)-D56LEF-1 reduces estradiol induced luciferase expression from pENP1-luc. The overexpression of D56LEF-1 construct reduced
the luciferase activity induced by estradiol from the pENP1-Luc plasmid, when compared with mock-transfected cells (empty-pcDNA3). Estradiol (E)
induced luciferase activity to 8–15 fold that of the control levels (C and E), in the pENP1-luc reporter. However, the expression of D56LEF-1
diminished this induction (compare pCDNA3+E versus D56+E). In both cases (C–D), the graphs show the normalized luciferase activity (RLU) from at
least three independent experiments. The P value from the Student’s t-test was * (P#0.05).
doi:10.1371/journal.pone.0005153.g006
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secreted prominently by D56LEF-1/N2a-m cells. Similarly, b-
catenin displayed weaker protein expression in D56LEF-1/N2a-m
cells, independently of the treatment.
Finally, a second set of genes were found, those that respond to
estradiol (and/or Wnt) in control cells and whose regulation was
modified by the presence of D56LEF-1. Indeed, longer treatment
enabled clear differences to be detected at the protein level in
genes such as N-cadherin and Cyclin D2. Our data indicated that
N-cadherin was upregulated by estradiol and Wnt, and that the
expression of D56LEF-1 almost completely blocked these effects
(Figure 9B). While Cyclin D2 behaved similarly, Cyclin D1
appeared to be unchanged and unaffected by treatments
(Figure 9B). On the other hand, E-cadherin was upregulated by
estradiol in control cells (Group A), whereas the presence of
D56LEF-1 generated an uncontrolled upregulation. This result
revealed an important role for LEF-1 in estrogen-regulated E-
cadherin expression.
Discussion
Estrogens may act through different mechanisms, the best
known of which involves their capacity to directly bind to and
dimerize estrogen receptors (ERs). This hormone-protein complex
can either bind directly to promoter estrogen response elements
(EREs), or act as a cofactor at non-ERE sites through the
interaction with other DNA-binding elements, such as AP-1, or c-
Jun [5,25–26]. A second mode of action is associated with the so-
called ‘‘non genomic’’ or ‘‘rapid’’ actions, that include the
activation of PKC, G-protein-coupled receptors, ERKs and
PI3K/Akt in different cell systems [8,27]. Regarding this theme,
we recently reported that ERa forms a protein complex with
GSK3 and b-catenin in the hippocampus of ovariectomized rats;
the action of estradiol dissociated b-catenin from the complex in a
manner that was clearly correlated with the inhibition of GSK3
[12]. The interaction of ERa with GSK3 does not appear to be
specific for neurons and indeed, it has recently been demonstrated
that ERa is also phosphorylated and modulated by GSK3 in other
cell types [28].
Estradiol, through a ‘‘rapid response’’, activated the
pathway Akt/GSK3, stabilized b-catenin, and modulates
TCF-mediated transcription, in neurons
We had initially found that the inhibition of GSK3 by estradiol
was correlated with the stabilization of b-catenin. Thus, our first
aim here was to determine whether the pool of b-catenin regulated
by estradiol acts as a co-transcriptional modulator using canonical
TCF-mediated transcription or alternatively, whether the stabili-
zation of b-catenin plays some other role. With this aim, we
selected a neuronal cell line easily amenable to transfection with a
TCF-reporter: the N2a-m cell line which expresses the a and b ER
receptors and accumulates nuclear ER when treated with
estradiol. Significantly, we detected a complex of b-catenin and
GSK3 in these cells following exposure to either ERa or ERb.
Figure 7. The LEF-1-DNA complex is detected in nuclear protein extracts and it is modulated by estradiol. (A)-Identification of the
specific band by competition with non-labeled wt oligonucleotides. Nuclear proteins were obtained from N2a-m cells treated for 30 minutes with
estradiol, ICI or Wnt3a, enabling specific TCF-DNA complexes to be detected. In control nuclear extracts the presence of a pre-established TCF-DNA
complex was detected, which augmented slightly in the presence of estradiol and that decreased upon ICI treatment. The arrow indicates the
complex. (B)-Analysis of the identity of the TCF-DNA complex. Antibodies against TCF1, LEF-1, or irrelevant IgGs (C) were added to the nuclear
protein extracts and modification of the DNA/protein complex was evaluated. In addition, antibodies against TCF3 or ERa were used in parallel
experiments, without producing any modification of this pattern (Supplementary Figure S4). Only in the case of the anti-LEF-1 antibody was a more
slowly migrating band observed. The arrow with an asterisk indicates the appearance of a higher molecular weight complex.
doi:10.1371/journal.pone.0005153.g007
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Figure 8. Generation of a stable N2a-m cell line expressing the D56LEF-1 protein. N2a-m cells were co-transfected with D56LEF-1 or the
empty pCDNA3 vector containing the Puromycin resistance gene (for details see Methods). (A)- N2a-m-D56LEF-1 expression was observed by dual
immunocytochemistry using an LEF-HMGbox antibody (green) and Phalloidin (red). Note the morphological changes associated with the expression
of LEF-1 mutant. (B)- RNA from the different stable N2a-m cell lines was obtained and the RT-PCR products were analyzed in agarose gels. Expression
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When N2a-m or cortical neurons were treated with estradiol, we
detected a similar biochemical response with an increase of GSK3
serine phosphorylation as well as the stabilization of b-catenin.
This inhibition of GSK3 was time- and concentration-dependent,
and these data are in essence similar to those described in the
hippocampus of ovariectomiced rats after estradiol treatment, or
in hippocampal neurons [12].
Taking into account these initial results, the question arose as to
whether b-catenin stabilized by estradiol might modulate tran-
scription. It is believed that b-catenin has two different and
complementary roles in cells; it may contribute to the cell-cell
adhesion or it may act as a co-transcriptional regulator of the TCF
family [16–19]. Our data first showed that estradiol activated
TCF-mediated transcription at concentrations of 1061029 M.
This nuclear activation of luciferase was time- and concentration-
dependent, it was maximal at 10–2061028 M, and it could be
abolished by the ER antagonist ICI 182780. Similar, but slightly
weaker transcriptional activation could be obtained with the ERa-
selective agonist, PPT (5–10 nM), as well with the ERb-selective
agonist, DPN (5–10 nM). All these data strongly suggested that
estradiol stabilizes b-catenin through ERa and ERb, and that at
least a portion of this protein pool can activate transcription. This
transcriptional activation depended on the phosphorylation status
of b-catenin. Indeed, the highest levels of transcription were
obtained with a mutated form of b-catenin (S33Y) that was
virtually unaffected by estradiol. These data raise the question as
to whether this TCF- b-catenin mediated transcription is similar to
that obtained with Wnt proteins.
We have also showed that estradiol may activate transcription
from a portion of the engrailed-1 promoter that contains well
characterized TCF elements (pENP1-luc) (McGrew et al. 1999),
and also activate transcription in primary neurons derived from
mice transgenic for a TCF-b-galactosidase reporter driving the
expression of a luciferase reporter. It is important to remember that
the estradiol-dependent transcription mediated by pENP1-luc is
severely inhibited by the expression a LEF-1 truncated-mutant
(D56LEF-1) [23]. We found that estradiol slightly augmented the
formation of DNA-TCF complexes, a similar effect to that
produced by exposure to Wnt3a. This transcriptional activation
is dependent on LEF-1, since antibodies against LEF-1 can disrupt
DNA-complex formation. Furthermore, the presence of D56LEF-
1 almost completely prevented estradiol-mediated transcription.
It was recently demonstrated that estradiol regulates LEF-1 and
Tcf3, and more importantly, that a complex containing ERa and
Tcf3/LEF-1 may be immunoprecipitated from mouse uterus
extracts [29]. Accordingly, it was proposed that a complex
composed of ERa/b-catenin/Tcf-3 is an important part of the
estradiol response in this tissue. Although we cannot completely
rule out this possibility (particularly since we did not use the same
methodology), in our experiments LEF-1 was not immunoprecip-
itated when antibodies against either ERa or b were used. Only
antibodies against LEF-1 prevented the formation of a DNA-
protein complex in EMSA assays, unlike antibodies against Tcf 3
or ERa. Indeed, the initial cytoplasmic ERa/b-catenin/GSK3
complex appears to be different, with the complex in uterus being
arranged (assembled?) after hormone addition, while in neural
cells and neurons the complex is detected even prior to hormone
treatment.
Further studies will be required to clarify whether the same
ERa/b-catenin/Tcf-3 complex observed in the uterus is also
present in neurons or in some specific brain regions. It will be
interesting analyzing other possible components that might
mediate the effect of the estrogen receptor on TCF/LEF-1
transcription, such as transducin beta-like protein 1 (TBL1) and its
highly related family member TBLR1 [30]; among many others
(see reviewed in [16–19]). A different point worthy of mention is
that we detected multiple ERa bands in N2A cell extracts and
after estradiol treatment only some of them appear to move into
the nuclear fraction. This observation opens some interesting
questions about the molecular nature of these multiple bands and
why only some of them are mobilized. We are currently initiating
the study of these ERa isoform/s in order to clarify the different
possibilities suggested by the bibliography (isoform versus proteol-
ysis??) [31–32].
Several publications have recently emerged in which new
elements have been described that regulate the Wnt-b-catenin
pathway. For example, c-Jun forms a complex with b-catenin and
Dvl in the nucleus, and this association regulates the transcrip-
tional activity of b-catenin [33]. Moreover, Rac1-JNK2 appears to
act as a novel modulator of b-catenin mediated transcription [34].
Thus, the complex regulation of b-catenin is becoming more
evident, as it is not only modulated through its cellular distribution
or phosphorylation, but also by the proteins with which it
associates. Here, we describe a novel pathway that regulates b-
catenin/TCF activity through a ligand, estradiol, using at least
some of the components of the original Wnt pathway.
Is the gene expression through LEF-1/b-catenin estradiol-
mediated similar to those triggered by Wnt?
To determine more specifically whether estradiol can regulate
gene expression using the TCF/LEF-1-b-catenin system in a way
similar to that of Wnt3a, we generated N2a-m cells stably
transfected with D56LEF-1 cDNA. By analyzing the gene
expression profile of these cell lines on an Aplied Biosystems
Mouse Genome Survey Microarray, we detected 223 genes
modified by estradiol; whereas Wnt3a modified 303 genes,
sensitive to D56LEF-1 (see Table 1, containing only the
annotated sequences).
To validate these changes, at the protein level, we had to extend
the treatment period and as a result, we selected some
representative genes from our array, such as Plg as well as some
genes that have been previously associated with Wnt stimuli, such
as E-Cadherin [35], Cyclin D [36–38], c-myc [39], LEF-1 [40–41]
and TCF-1 [42]. We used commercially available antibodies to
validate the changes in the levels of these proteins in the presence
of D56LEF-1 and/or the hormone or Wnt. Our data revealed two
major types of response: first, those genes modified initially by the
of the D56LEF-1 plasmid was tested using oligos specific to the D56LEF-1 plasmid, in parallel with specific oligos recognizing endogenous LEF-1
protein (LEF-1-wt) as controls. Note that no significant differences in plasmid expression were observed between cells growing in 10% FCS compared
to those grown in the absence of FCS. (C)-Protein expression was determined to test for the presence of the mutant LEF-1 protein in N2a-m cells.
Nuclear extracts were prepared from control and estradiol treated cells, and little accumulation of b-catenin was detected after exposure to estradiol
although the estrogen receptor does enter the nucleus. The LEF-HMG box antibody allows us to differentiate full-length LEF-1 from D56 LEF-1 in
western blots. Nucleolin levels were used as an internal control. The right insert represents the luciferase activity (RLU) of both stable cell lines. A
functional analysis was performed to check the loss of estradiol induction over TOPFlash in these cells, as previously reported for the transient
transfection (Figure 6C). The graph shows the normalized luciferase activity from at least three independent experiments. The P value from the
Student’s t-test was ** (P#0.01) when compared with control data.
doi:10.1371/journal.pone.0005153.g008
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Table 1. Results of the Microarray analysis of gene transcription.
UPREGULATED:
RefSeq_NM est_A vs B Gene_Name
NM_007990.1 2,739 Finkel-Biskis-Reilly murine sarcoma virus (FBR-MuSV) ubiquitously expressed (fox derived)
NM_133198.1 2,676 liver glycogen phosphorylase
NM_130888.1 2,457 nuclear RNA export factor 7
NM_025703.2 2,439 RIKEN cDNA 3930402F23 gene
NM_183271.1 2,181 RIKEN cDNA 1700049M11 gene
NM_008877.2 2,039 plasminogen
NM_007407.2 2,034 adenylate cyclase activating polypeptide 1 receptor 1
D87975.1 1,994 serine (or cysteine) proteinase inhibitor, clade F, member 1
NM_019703.2 1,890 phosphofructokinase, platelet
NM_010480.4 1,847 heat shock protein 1, alpha
NM_054095.1 1,846 EF hand calcium binding protein 2
NM_013779.1 1,701 melanoma antigen, family L, 2
NM_021389.3 1,653 SH3-domain kinase binding protein 1
NM_009529.1 1,509 Xlr-related, meiosis regulated
NM_133362.1 1,491 erythroid differentiation regulator 1
NM_183294.1 1,487 cyclin-dependent kinase-like 1 (CDC2-related kinase)
NM_007833.1 1,462 decorin
BC053970.1 1,337 NADH dehydrogenase (ubiquinone) 1, alpha/beta subcomplex, 1
NM_008144.3 1,335 Bernardinelli-Seip congenital lipodystrophy 2 homolog (human)
NM_033325.1 1,332 lysyl oxidase-like 2
NM_175027.2 1,321 cDNA sequence BC022692
NM_146034.1 1,316 meningioma expressed antigen 6 (coiled-coil proline-rich)
NM_177752.2 1,313 hypothetical protein 6820428D13
NM_025437.2 1,298 eukaryotic translation initiation factor 1A, Y-linked
NM_019768.2 1,291 mortality factor 4 like 2
NM_008590.1 1,251 mesoderm specific transcript
NM_019647.3 1,247 ribosomal protein L21
NM_031174.2 1,246 Down syndrome cell adhesion molecule
NM_009093.1 1,237 ribosomal protein S29
NM_008200.1 1,225 histocompatibility 2, D region locus 4
NM_008033.2 1,222 farnesyltransferase, CAAX box, alpha
NM_026712.1 1,216 RIKEN cDNA 0610030H11 gene
NM_183203.1 1,202 hypothetical protein 9130430E04
NM_145628.2 1,200 ubiquitin specific protease 11
NM_207204.1 1,188 RIKEN cDNA 4930519N13 gene
NM_025695.2 1,178 SMC6 structural maintenance of chromosomes 6-like 1 (yeast)
NM_008183.2 1,177 glutathione S-transferase, mu 2
NM_145526.1 1,173 purinergic receptor P2X, ligand-gated ion channel, 3
NM_012035.1 1,136 transient receptor potential cation channel, subfamily C, member 7
NM_010206.1 1,135 fibroblast growth factor receptor 1
NM_146035.1 1,122 mannoside acetylglucosaminyltransferase 2
NM_175930.2 1,118 Rap guanine nucleotide exchange factor (GEF) 5
NM_013819.1 1,111 histocompatibility 2, M region locus 3
NM_008666.1 1,094 myelin transcription factor 1-like
NM_029823.1 1,092 RIKEN cDNA 6530401D17 gene
NM_172758.1 1,090 cDNA sequence BC031853
AK040457.1 1,085 interleukin 27 receptor, alpha
NM_194355.1 1,079 spire homolog 1 (Drosophila)
NM_007881.4 1,072 dentatorubral pallidoluysian atrophy
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UPREGULATED:
RefSeq_NM est_A vs B Gene_Name
NM_025522.1 1,064 dehydrogenase/reductase (SDR family) member 7
NM_008549.1 1,063 mannosidase 2, alpha 1
NM_010545.2 1,058 Ia-associated invariant chain
NM_008810.2 1,058 pyruvate dehydrogenase E1 alpha 1
NM_175007.1 1,044 amphiphysin
NM_028270.2 1,029 aldehyde dehydrogenase 1 family, member B1
NM_008737.1 1,024 neuropilin
NM_008666.1 1,023 myelin transcription factor 1-like
NM_025932.1 1,016 synapse associated protein 1
NM_010195.1 1,006 G protein-coupled receptor 49
DOWNREGULATED:
RefSeq_NM est_AvsB Gene_Name
NM_019932.1 23,893 chemokine (C-X-C motif) ligand 4
NM_010703.2 22,642 lymphoid enhancer binding factor 1
NM_013492.1 22,293 clusterin
NM_011702.1 22,053 vasoactive intestinal polypeptide
NM_010685.2 21,992 lysosomal membrane glycoprotein 2
NM_011333.1 21,986 chemokine (C-C motif) ligand 2
NM_010658.2 21,809 v-maf musculoaponeurotic fibrosarcoma oncogene family, protein B (avian)
NM_010515.1 21,705 insulin-like growth factor 2 receptor
AK033214.1 21,677 G elongation factor
BC053489.1 21,557 insulin-like growth factor 2
NM_023422.1 21,438 histone 1, H2bc
AK027922.1 21,427 glutathione S-transferase omega 1
NM_177708.3 21,420 reticulon 4 receptor-like 1
NM_175395.2 21,418 RIKEN cDNA 1700001A24 gene;RIKEN cDNA 6330578E17 gene
NM_053273.1 21,410 tweety homolog 2 (Drosophila)
NM_009344.1 21,395 pleckstrin homology-like domain, family A, member 1
NM_011844.3 21,349 monoglyceride lipase
NM_009776.1 21,346 serine (or cysteine) proteinase inhibitor, clade G, member 1
NM_021274.1 21,339 chemokine (C-X-C motif) ligand 10
NM_021897.1 21,337 transformation related protein 53 inducible nuclear protein 1
NM_138683.1 21,303 thrombospondin type 1 domain containing gene
NM_010789.1 21,292 myeloid ecotropic viral integration site 1
NM_016867.1 21,291 semaF cytoplasmic domain associated protein 2
BC058269.1 21,290 RAR-related orphan receptor beta
NM_007635.2 21,279 cyclin G2
NM_015818.1 21,275 heparan sulfate 6-O-sulfotransferase 1
NM_026416.2 21,261 S100 calcium binding protein A16
NM_145825.1 21,260 centrin 4
AK035160.1 21,252 heart and neural crest derivatives expressed transcript 2
NM_028535.1 21,251 RIKEN cDNA 1700049E17 gene
AK031672.1 21,246 DNA segment, Chr 11, ERATO Doi 498, expressed
NM_178405.2 21,233 ATPase, Na+/K+ transporting, alpha 2 polypeptide
NM_172854.1 21,213 RIKEN cDNA 4932431K08 gene
NM_009242.1 21,180 secreted acidic cysteine rich glycoprotein
NM_021537.2 21,172 serine/threonine kinase 25 (yeast)
Table 1. cont.
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DOWNREGULATED:
RefSeq_NM est_AvsB Gene_Name
NM_008250.1 21,167 H2.0-like homeo box gene
NM_008538.2 21,167 myristoylated alanine rich protein kinase C substrate
NM_026793.1 21,166 myc target 1
NM_011353.1 21,163 small EDRK-rich factor 1
NM_026358.1 21,160 RIKEN cDNA 4930583H14 gene
NM_009726.2 21,158 ATPase, Cu++ transporting, alpha polypeptide
NM_194268.2 21,155 one cut domain, family member 2
NM_011295.2 21,142 ribosomal protein S12
NM_175103.2 21,135 RIKEN cDNA 1110025L05 gene
NM_025836.1 21,130 mannose-6-phosphate receptor binding protein 1
NM_025692.1 21,127 ubiquitin-activating enzyme E1-domain containing 1
NM_025394.1 21,126 translocase of outer mitochondrial membrane 7 homolog (yeast)
NM_028279.1 21,125 N-acetylated alpha-linked acidic dipeptidase 2
NM_133780.2 21,125 translocated promoter region
NM_013660.1 21,120 sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain,
(semaphorin) 4D
NM_013692.1 21,120 TGFB inducible early growth response 1
NM_010357.1 21,119 glutathione S-transferase, alpha 4
NM_018865.1 21,108 WNT1 inducible signaling pathway protein 1
NM_010317.2 21,107 guanine nucleotide binding protein (G protein), gamma 4 subunit
NM_173788.2 21,101 natriuretic peptide receptor 2
NM_175238.4 21,089 DNA segment, Chr 2, ERATO Doi 145, expressed
NM_011313.1 21,088 S100 calcium binding protein A6 (calcyclin)
NM_025735.1 21,080 microtubule-associated protein 1 light chain 3 alpha
NM_178751.2 21,080 RIKEN cDNA A730041O15 gene
NM_030037.1 21,078 motile sperm domain containing 3
NM_017367.2 21,078 cyclin I
NM_133218.1 21,077 glucocorticoid induced gene 1
AK010069.1 21,075 DNA segment, Chr 7, Wayne State University 87, expressed
NM_026033.1 21,074 ocular development associated gene
NM_021398.1 21,070 solute carrier family 43, member 3
NM_174988.2 21,063 cadherin 22
NM_026111.2 21,043 RIKEN cDNA 1810019P04 gene
NM_012057.1 21,042 interferon regulatory factor 5
AK076923.1 21,042 protein phosphatase 1B, magnesium dependent, beta isoform
NM_133859.1 21,040 olfactomedin-like 3
NM_026565.2 21,038 RIKEN cDNA 9430083G14 gene
NM_133942.1 21,037 expressed sequence AA960558
AK003039.1 21,030 glycolipid transfer protein
NM_008967.1 21,022 prostaglandin I receptor (IP)
NM_023649.1 21,020 Usher syndrome 1C homolog (human)
NM_025946.2 21,013 RIKEN cDNA 2010100O12 gene
NM_009113.2 21,010 S100 calcium binding protein A13
NM_027285.1 21,009 RIKEN cDNA 1700029I01 gene
NM_172296.1 21,009 doublesex and mab-3 related transcription factor like family A2
NM_009814.1 21,007 calsequestrin 2
NM_013765.1 21,005 ribosomal protein S26
NM_011952.1 21,003 mitogen activated protein kinase 3
Table 1. cont.
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DOWNREGULATED:
RefSeq_NM est_AvsB Gene_Name
NM_010831.1 21,001 SNF1-like kinase
UPREGULATED:
RefSeq_NM Wnt_AvsB Gene_Symbol Gene_Name
NM_007990.1 3,603 Fau Finkel-Biskis-Reilly murine sarcoma virus (FBR-MuSV) ubiquitously
expressed (fox derived)
NM_133198.1 2,620 Pygl liver glycogen phosphorylase
NM_019703.2 2,343 Pfkp phosphofructokinase, platelet
NM_007407.2 2,294 Adcyap1r1 adenylate cyclase activating polypeptide 1 receptor 1
NM_025703.2 2,270 3930402F23Rik RIKEN cDNA 3930402F23 gene
NM_183271.1 2,215 1700049M11Rik RIKEN cDNA 1700049M11 gene
BC053970.1 2,198 Ndufab1 NADH dehydrogenase (ubiquinone) 1, alpha/beta subcomplex, 1
NM_130888.1 2,106 Nxf7 nuclear RNA export factor 7
D87975.1 2,052 Serpinf1 serine (or cysteine) proteinase inhibitor, clade F, member 1
NM_021389.3 1,966 Sh3kbp1 SH3-domain kinase binding protein 1
NM_054095.1 1,910 Efcbp2 EF hand calcium binding protein 2
NM_133362.1 1,797 Erdr1 erythroid differentiation regulator 1
NM_177752.2 1,682 6820428D13 hypothetical protein 6820428D13
NM_172960.1 1,608 Adck5 aarF domain containing kinase 5
AK040457.1 1,501 Il27ra interleukin 27 receptor, alpha
NM_008595.1 1,446 Mfng manic fringe homolog (Drosophila)
NM_033325.1 1,445 Loxl2 lysyl oxidase-like 2
NM_145526.1 1,425 P2rx3 purinergic receptor P2X, ligand-gated ion channel, 3
NM_008183.2 1,419 Gstm2 glutathione S-transferase, mu 2
NM_025695.2 1,414 Smc6l1 SMC6 structural maintenance of chromosomes 6-like 1 (yeast)
NM_009369.1 1,414 Tgfbi transforming growth factor, beta induced
NM_025522.1 1,410 Dhrs7 dehydrogenase/reductase (SDR family) member 7
NM_007997.1 1,399 Fdxr ferredoxin reductase
NM_207204.1 1,382 4930519N13Rik RIKEN cDNA 4930519N13 gene
NM_007833.1 1,360 Dcn decorin
NM_008877.2 1,342 Plg plasminogen
NM_019966.1 1,331 Mlycd malonyl-CoA decarboxylase
NM_175027.2 1,316 BC022692 cDNA sequence BC022692
NM_080553.1 1,309 Itpr3 inositol 1,4,5-triphosphate receptor 3
NM_010480.4 1,308 Hspca heat shock protein 1, alpha
NM_029823.1 1,273 6530401D17Rik RIKEN cDNA 6530401D17 gene
NM_008144.3 1,273 Bscl2 Bernardinelli-Seip congenital lipodystrophy 2 homolog (human)
NM_198031.1 1,266 Tubgcp3 tubulin, gamma complex associated protein 3
NM_008810.2 1,249 Pdha1 pyruvate dehydrogenase E1 alpha 1
NM_008666.1 1,246 Myt1l myelin transcription factor 1-like
NM_173427.1 1,240 B230308G19Rik RIKEN cDNA B230308G19 gene
NM_178794.2 1,234 U2af1-rs2 U2 small nuclear ribonucleoprotein auxiliary factor (U2AF) 1, related
sequence 2
NM_146034.1 1,234 Mgea6 meningioma expressed antigen 6 (coiled-coil proline-rich)
NM_019552.1 1,229 Abcb10 ATP-binding cassette, sub-family B (MDR/TAP), member 10
NM_178915.2 1,221 AI839735 expressed sequence AI839735
NM_008243.2 1,215 Mst1 macrophage stimulating 1 (hepatocyte growth factor-like)
NM_145482.1 1,175 ORF21 open reading frame 21
NM_025936.1 1,173 Rars arginyl-tRNA synthetase
NM_028262.1 1,168 D12Ertd771e DNA segment, Chr 12, ERATO Doi 771, expressed
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UPREGULATED:
RefSeq_NM Wnt_AvsB Gene_Symbol Gene_Name
NM_031174.2 1,164 Dscam Down syndrome cell adhesion molecule
NM_023304.1 1,149 Fgf22 fibroblast growth factor 22
NM_025932.1 1,139 Syap1 synapse associated protein 1
NM_013778.1 1,130 Akr1c13;Akr1c12 aldo-keto reductase family 1, member C13;aldo-keto reductase family 1,
member C12
NM_013819.1 1,129 H2-M3 histocompatibility 2, M region locus 3
NM_007407.2 1,126 Adcyap1r1 adenylate cyclase activating polypeptide 1 receptor 1
NM_021273.2 1,122 Ckb creatine kinase, brain
NM_008033.2 1,119 Fnta farnesyltransferase, CAAX box, alpha
NM_009529.1 1,115 Xmr Xlr-related, meiosis regulated
NM_207269.1 1,111 D330050I23Rik RIKEN cDNA D330050I23 gene
NM_010752.1 1,108 Mad1l1 mitotic arrest deficient 1-like 1
NM_028089.1 1,091 Cyp2c55 cytochrome P450, family 2, subfamily c, polypeptide 55
NM_133224.1 1,090 Atp13a ATPase type 13A
NM_025656.1 1,089 Sip1 survivor of motor neuron protein interacting protein 1
NM_028002.1 1,088 2310069P03Rik RIKEN cDNA 2310069P03 gene
NM_010724.1 1,086 Psmb8 proteosome (prosome, macropain) subunit, beta type 8
NM_028131.1 1,081 2610510J17Rik RIKEN cDNA 2610510J17 gene
NM_009239.1 1,080 Sp4 trans-acting transcription factor 4
NM_025437.2 1,077 Eif1ay eukaryotic translation initiation factor 1A, Y-linked
NM_183294.1 1,072 Cdkl1 cyclin-dependent kinase-like 1 (CDC2-related kinase)
NM_013779.1 1,070 Magel2 melanoma antigen, family L, 2
NM_021556.2 1,063 Mrps30 mitochondrial ribosomal protein S30
NM_207210.1 1,059 Dyrk4 dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 4
NM_146035.1 1,057 Mgat2 mannoside acetylglucosaminyltransferase 2
NM_144844.1 1,049 Pcca propionyl-Coenzyme A carboxylase, alpha polypeptide
NM_178389.2 1,045 Gale galactose-4-epimerase, UDP
NM_012035.1 1,041 Trpc7 transient receptor potential cation channel, subfamily C, member 7
NM_176953.2 1,034 Lig4 ligase IV, DNA, ATP-dependent
NM_008183.2 1,033 Gstm2 glutathione S-transferase, mu 2
NM_178242.2 1,032 Zfp469 zinc finger protein 469
NM_009933.1 1,030 Col6a1 procollagen, type VI, alpha 1
NM_010068.1 1,030 Dnmt3b DNA methyltransferase 3B
NM_028270.2 1,027 Aldh1b1 aldehyde dehydrogenase 1 family, member B1
NM_172783.1 1,022 Phka2 phosphorylase kinase alpha 2
NM_008590.1 1,020 Mest mesoderm specific transcript
NM_013761.2 1,017 Srr serine racemase
NM_029541.1 1,017 6530401D17Rik RIKEN cDNA 6530401D17 gene
NM_025486.1 1,012 1700006C06Rik RIKEN cDNA 1700006C06 gene
NM_130864.2 1,012 Acaa1 acetyl-Coenzyme A acyltransferase 1
DOWNREGULATED:
RefSeq_NM Wnt_AvsB Gene_Symbol Gene_Name
NM_019932.1 23,616 Cxcl4 chemokine (C-X-C motif) ligand 4
NM_010703.2 23,395 Lef1 lymphoid enhancer binding factor 1
NM_011702.1 22,102 Vip vasoactive intestinal polypeptide
NM_010685.2 22,085 Lamp2 lysosomal membrane glycoprotein 2
NM_011333.1 21,843 Ccl2 chemokine (C-C motif) ligand 2
AK027922.1 21,770 Gsto1 glutathione S-transferase omega 1
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DOWNREGULATED:
RefSeq_NM Wnt_AvsB Gene_Symbol Gene_Name
NM_010515.1 21,748 Igf2r insulin-like growth factor 2 receptor
NM_007635.2 21,679 Ccng2 cyclin G2
NM_013492.1 21,634 Clu clusterin
NM_027285.1 21,585 1700029I01Rik RIKEN cDNA 1700029I01 gene
NM_177708.3 21,583 Rtn4rl1
NM_016867.1 21,571 Semcap2 semaF cytoplasmic domain associated protein 2
NM_009150.2 21,552 Selenbp2;Selenbp1 selenium binding protein 2;selenium binding protein 1
NM_177820.2 21,484 9130218O11Rik RIKEN cDNA 9130218O11 gene
NM_009726.2 21,423 Atp7a ATPase, Cu++ transporting, alpha polypeptide
NM_026416.2 21,393 S100a16 S100 calcium binding protein A16
NM_023422.1 21,390 Hist1h2bc histone 1, H2bc
NM_009760.2 21,378 Bnip3 BCL2/adenovirus E1B 19kDa-interacting protein 1, NIP3
NM_030037.1 21,334 Mospd3 motile sperm domain containing 3
NM_010149.2 21,323 Epor erythropoietin receptor
NM_172296.1 21,305 Dmrta2 doublesex and mab-3 related transcription factor like family
A2
AK076923.1 21,305 Ppm1b protein phosphatase 1B, magnesium dependent, beta isoform
NM_026030.1 21,298 Eif2s2 eukaryotic translation initiation factor 2, subunit 2 (beta)
NM_194268.2 21,294 Onecut2 one cut domain, family member 2
NM_008926.2 21,293 Prkg2 protein kinase, cGMP-dependent, type II
NM_026565.2 21,291 9430083G14Rik RIKEN cDNA 9430083G14 gene
NM_025949.1 21,279 Rps6ka6 ribosomal protein S6 kinase polypeptide 6
NM_009242.1 21,264 Sparc secreted acidic cysteine rich glycoprotein
NM_178405.2 21,256 Atp1a2 ATPase, Na+/K+ transporting, alpha 2 polypeptide
NM_007874.2 21,237 Dp1 deleted in polyposis 1
NM_026793.1 21,236 Myct1 myc target 1
NM_177603.1 21,228 Frat2 frequently rearranged in advanced T-cell lymphomas 2
NM_025836.1 21,224 M6prbp1 mannose-6-phosphate receptor binding protein 1
NM_028535.1 21,224 1700049E17Rik RIKEN cDNA 1700049E17 gene
NM_026358.1 21,221 4930583H14Rik RIKEN cDNA 4930583H14 gene
NM_172132.1 21,218 Jmjd2b jumonji domain containing 2B
AK005820.1 21,210 Rabl5 RAB, member of RAS oncogene family-like 5
AK049314.1 21,193 Trim27 tripartite motif protein 27
NM_017367.2 21,188 Ccni cyclin I
NM_009814.1 21,180 Casq2 calsequestrin 2
NM_009101.1 21,174 Rras Harvey rat sarcoma oncogene, subgroup R
AK003039.1 21,174 Gltp glycolipid transfer protein
NM_008467.2 21,172 Kpna4 karyopherin (importin) alpha 4
BC038145.1 21,172 BC002199 cDNA sequence BC002199
NM_133780.2 21,168 Tpr translocated promoter region
NM_177798.3 21,157 Frs2 fibroblast growth factor receptor substrate 2
NM_008906.2 21,153 Ppgb protective protein for beta-galactosidase
NM_015818.1 21,152 Hs6st1 heparan sulfate 6-O-sulfotransferase 1
NM_009113.2 21,152 S100a13 S100 calcium binding protein A13
NM_009344.1 21,148 Phlda1 pleckstrin homology-like domain, family A, member 1
NM_019675.2 21,148 Stmn4 stathmin-like 4
NM_146141.1 21,147 1110013G13Rik RIKEN cDNA 1110013G13 gene
NM_009140.1 21,146 Cxcl2 chemokine (C-X-C motif) ligand 2
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DOWNREGULATED:
RefSeq_NM Wnt_AvsB Gene_Symbol Gene_Name
NM_173788.2 21,145 Npr2 natriuretic peptide receptor 2
NM_021274.1 21,144 Cxcl10 chemokine (C-X-C motif) ligand 10
AK052456.1 21,142 D430026P16Rik RIKEN cDNA D430026P16 gene
NM_153399.1 21,140 Syne1 synaptic nuclear envelope 1
NM_011756.3 21,136 Zfp36 zinc finger protein 36
AK083556.1 21,136 Fst follistatin
NM_026033.1 21,122 Odag ocular development associated gene
NM_031997.2 21,121 Tmem2 transmembrane protein 2
NM_178772.2 21,117 B230106I24Rik RIKEN cDNA B230106I24 gene
NM_011353.1 21,112 Serf1 small EDRK-rich factor 1
NM_021398.1 21,110 Slc43a3 solute carrier family 43, member 3
NM_027482.1 21,095 5730508B09Rik RIKEN cDNA 5730508B09 gene
NM_133777.1 21,087 Ube2s ubiquitin-conjugating enzyme E2S
NM_012057.1 21,083 Irf5 interferon regulatory factor 5
NM_013660.1 21,080 Sema4d sema domain, immunoglobulin domain (Ig), (semaphorin) 4D
NM_146260.1 21,080 Tmie transmembrane inner ear
NM_153068.1 21,075 Ehd2 EH-domain containing 2
NM_138584.1 21,074 Spg21 spastic paraplegia 21 homolog (human)
NM_011295.2 21,073 Rps12 ribosomal protein S12
NM_030696.2 21,071 Slc16a3 solute carrier family 16 (monocarboxylic acid transporters),
member 3
NM_130903.2 21,068 Cd209c CD209c antigen
NM_020586.1 21,068 5031400M07Rik RIKEN cDNA 5031400M07 gene
NM_031997.2 21,067 Tmem2 transmembrane protein 2
NM_010789.1 21,065 Meis1 myeloid ecotropic viral integration site 1
NM_011498.2 21,065 Bhlhb2 basic helix-loop-helix domain containing, class B2
NM_025290.2 21,063 Tsga2 testis specific gene A2
NM_139144.2 21,063 Ogt O-linked N-acetylglucosamine (GlcNAc) transferase (UDP-N-
acetylglucosamine:polypeptide-N-acetylglucosaminyl
transferase)
NM_009895.2 21,059 Cish cytokine inducible SH2-containing protein
NM_011171.1 21,057 Procr protein C receptor, endothelial
NM_019880.2 21,056 Mtch1 mitochondrial carrier homolog 1 (C. elegans)
NM_010658.2 21,056 Mafb v-maf musculoaponeurotic fibrosarcoma oncogene family,
protein B (avian)
NM_011046.1 21,054 Furin furin (paired basic amino acid cleaving enzyme)
NM_011252.2 21,053 Rbmx RNA binding motif protein, X chromosome
NM_007585.2 21,047 Anxa2 annexin A2
NM_025348.1 21,045 Ndufa3 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 3
BC028655.1 21,044 Solt SoxLZ/Sox6 leucine zipper binding protein in testis
NM_028279.1 21,043 Naalad2 N-acetylated alpha-linked acidic dipeptidase 2
NM_018865.1 21,040 Wisp1 WNT1 inducible signaling pathway protein 1
NM_178751.2 21,038 A730041O15Rik RIKEN cDNA A730041O15 gene
NM_029688.2 21,037 Npn3 neoplastic progression 3
NM_013692.1 21,031 Tieg1 TGFB inducible early growth response 1
NM_013525.1 21,025 Gas5 growth arrest specific 5
NM_175395.2 21,023 1700001A24Rik; 6330578E17Rik RIKEN cDNA 1700001A24 gene;RIKEN cDNA 6330578E17 gene
NM_019704.1 21,023 C78915 expressed sequence C78915
NM_010234.2 21,022 Fos FBJ osteosarcoma oncogene
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LEF-1 mutant background, such as Plasminogen, LEF-1 , b-
catenin and MMP-2, and second, a group of genes which initially
responded to estradiol, either positively or negatively, and
additionally showed an increased response in the D56LEF-1 cells,
such as N-Cadherin, E-Cadherin and Cyclin D2. Indeed, the
CyclinD2 promoter is clearly regulated by the estrogen receptor as
well as by TCFs, although its responsiveness to Wnt proteins has
also been assessed [36,38]. Our data indicate that in neurons, this
gene may be regulated by both elements, at least in part via b-
catenin/LEF-1.
Taken together, these data demonstrate the existence of a new
pathway controlled by estradiol, at least in neurons. Our data
show that this pathway contains some elements that may belong to
the canonical Wnt-pathway. Indeed some reports indicate that
estradiol may control the response of the Wnt pathway as an
important part of its neuroprotective role. This neuroprotective
response is mediated by increase of Wnt3a and inhibition of Dkk1
elevation, triggered after cerebral ischemia [43]. More work is now
required to identify whether a similar mechanism is specific for
certain types of brain insults or represents a more general
mechanism. The analysis of our arrays (Table 1) supports the
hypothesis that only part of the estradiol response sensitive to LEF-
1, is similar to Wnt3a response sensitive to LEF-1. This open the
possibility that in addition of collaborate with the Wnt response,
estradiol may regulated a pool genes (b-catenin/LEF-1- directed),
independently of Wnt status.
‘‘Neuroprotective role’’ of estradiol and GSK3 inhibition
A complementary and important aspect of our data is that
estradiol modulates the kinase activity of GSK3 irrespective of the
neuronal source, and consequently the stabilization of b-catenin is
an important event in these so called ‘‘non-genomic actions’’.
When considering the role of GSK3 and b-catenin in neurode-
generation [44], such as in relation to Alzheimer’s disease or
ischemia, some of the functional effects of estradiol may, at least in
part, represent an important physiological control of this kinase
[15]. We have to remember that in model systems of b-amyloid-
mediated toxicity, similar concentrations of estradiol may protect
neurons [15,45,46].
Estrogens play an important role in normal brain development
[47,48]. In addition, this hormone appears to exert a more general
neuroprotective effect such as in mouse models of Parkinson’s
disease [49–53] or after brain ischemia [54–58]. In some ischemia
models the estradiol–mediated GSK3 response, appears to be JNK-
Dkk1-dependent [43], and we cannot discard this possibility in our
neuronal system. However, our data indicate that the estradiol-
mediated inhibition of GSK3 is PI3K-Akt dependent (O. Varea et
al., unpublished data). It will be very important to determine
whether the response that we observed is specific to ‘‘immature
neurons’’ or whether it represents a more general mechanism.
Materials and Methods
Primary Cortical neurons and Neuroblastoma N2a-m
Mice were treated following the guidelines of Council of Europe
Convention ETS123, recently revised as indicated in the Directive
86/609/EEC. In addition all protocols were approved by the
institutional animal care and use committee. Cortical neurons
were obtained from E18 mouse embryos after isolating the cortex
in Ca2+- and Mg2+-free Hanks Buffer Salt Solution (HBSS 16,
GIBCO). Once 8–10 embryonic cortices were obtained, they were
finely cited, washed twice in HBSS 16 buffer,and incubated in
0.25% trypsin (GIBCO) and 1 mg/ml DNAse (Roche) for 15 min
at 37uC. Trypsin and DNAse were then eliminated by washing
three times, with HBSS 16, and the cut tissue was then triturated
using a siliconized pipette. The cells were counted and plated in a
poly-lysine coated (1 mg/ml, Sigma) 60 mm dish containing
plating medium (MEM, 20% Glucose, horse serum and
antibiotics). After 3 hours plating, the medium was changed to
phenol red-free Neurobasal medium supplemented with B-B27
GIBCO) and the neurons were maintained under these conditions
for 2 days. Murine neuroblastoma N2a-m cells were grown at
37uC in 7% CO2, in DMEM supplemented with 10% fetal calf
serum (GIBCO) and 2 mM glutamine.
Cell treatments. One day before treatment, the medium was
changed to serum and phenol red free-medium The compounds
used for treatments were: 17-b-estradiol (stored in ethanol at a
concentration of 1 mM), ICI 182780 (Tocris, stored in dimethyl
DOWNREGULATED:
RefSeq_NM Wnt_AvsB Gene_Symbol Gene_Name
NM_011594.2 21,020 Timp2 tissue inhibitor of metalloproteinase 2
NM_198420.1 21,019 D15Wsu169e DNA segment, Chr 15, Wayne State University 169, expressed
NM_008662.1 21,018 Myo6 myosin VI
AK033214.1 21,018 Gfm G elongation factor
NM_010885.2 21,013 Ndufa2 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 2
NM_027287.1 21,007 Dnajb4 DnaJ (Hsp40) homolog, subfamily B, member 4
NM_133942.1 21,006 AA960558 expressed sequence AA960558
NM_007664.1 21,005 Cdh2 cadherin 2
NM_027189.1 21,004 Gemin7 gem (nuclear organelle) associated protein 7
NM_009627.1 21,001 Adm adrenomedullin
This Table represent a selection of annotated genes upregulated (red) and downregulated (green) by estradiol, sensitive to LEF-1 mutant. The list contains only those
‘‘annotated genes’’ with a log2R higher or lower than 1. A represent the control cell line (N2a-m-mock transfected). B represents the cell line transfected with delta-56-
LEF-1. In the table est, represents treatment with estradiol; and Wnt, treatment with Wnt3a.
We labeled two genes (plasminogen and LEF-1) regulated by estradiol or by Wnt3a , both were subsequently validated at protein level.
doi:10.1371/journal.pone.0005153.t001
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sulfoxide -DMSO- at 2 mM), Wnt3a recombinant protein (R&D
systems, dissolved in PBS-BSA 0.1% and stored at 0.1 mg/ml), and
the estrogen receptor agonists, 4,49,40-(propyl-[(1)H]-pyrazole-1,3,5-
triyl) trisphenol (PPT, a-selective) and 2,3-bis (4-hydroxyphenyl)
propionitrile (DPN (b-selective) agonists, both dissolved in ethanol.
Different concentrations of these compounds were used as indicated
for each experiment and the controls received the vehicle of each
compound alone, ethanol in the case of estradiol, DMSO for ICI
182780 and PBS-BSA 0.1% as control for Wnt3a. The final
concentration of ICI 182780 used was depending on the
concentration of estradiol, in a ICI/estradiol ratio of 100 times.
Western Blotting and Antibodies
After two washes with PBS, cell extracts were prepared in lysis
buffer containing 200 mMHepes pH 7.4, 100 mMNaCl, 100 mM
NaF, 1 mM Na3VO4, 5 mM EDTA, 1% Triton and a protease
inhibitor cocktail (Roche). The cells were left for 30 min on ice in
this lysis buffer and then collected with a cell scraper. After adding
loading buffer, the samples were boiled for 10 min and resolved by
Tris/Glycine SDS-Polyacrylamide gel electrophoresis, and the
proteins were then transferred to a nitrocellulose membrane
(Amersham) in the presence of 20% methanol and 0.1% SDS.
Non-specific signals were blocked by incubating the membrane in
PBS-Tween-20 (PBT) and 5% milk for 2 h. The antibodies used to
probe the membranes were raised against: Ct ERa 1:800 (MC-20,
Santa Cruz), ERb 1:1000 (H-150, Santa Cruz), GSK3 a/b 1:1000
(Cell signalling), GSKPSer9, 21 1:1000 (Cell Signalling), b-catenin
1:800 (Transduction Labs), non-phospho b-catenin 1:800 (Upstate),
actin 1:2000 (Sigma), LEF-1 HMG box 1:800 (Sigma), cyclin D1
1:1000 (Santa Cruz), cyclin D2 1:1000 (MBL), N cadherin 1:1000
(Sigma), E cadherin 1:800 (Santa Cruz), MMP2 1:200 (Santa Cruz),
nucleolin 1:1000 (Santa Cruz), beta-galactosidase (ICN Biomed-
Cappel), b-III tubulin (Chemicon). These antibodies were then
detected with horseradish peroxidase conjugated secondary anti-
bodies (Amersham) used at a dilution of 1:5000.
Immunocytochemistry
To study the localization of proteins by immunocytochemistry,
we fixed cells plated at low density with 4% paraformaldehyde for
20 min at RT. After 3 washes for 10 min in PBS, fixed-cells were
incubated with 50 mM NH4Cl and then blocked and permeabi-
lized for 30 min with 1% fetal calf serum and 0.1% Triton-X-100
in PBS. The cells were incubated with the primary antibodies for
2 h at RT and after 3 washes with blocking solution, the secondary
Alexa fluor-488 or 594 antibodies were added (1:1000, Molecular
Probes). The primary antibodies used were raised against
b-catenin (1:400, Transduction Labs) or ERa (1:500, MC-20,
Santa Cruz). To visualize the distribution of polymerized actin,
fixed cells were stained with phalloidin conjugated to Alexa 488 or
594, as indicated in each experiment (1:100, Molecular Probes).
Coverslips were mounted with Fluoromount G (Southern
Biotechnology Associates, Inc) and photographs were taken on a
confocal microscope (LSM 510 META, Zeiss).
Plasmids and Transient expression in N2a-m cells
The plasmids used for transient expression were: pTOPFlash
(Upstate), containing three copies of the consensus sequence
recognized by the TCF/LEF transcription factors
(CCTTTGATC) and with the c-Fos promoter driving the
expression of luciferase gene; pFOPFlash (Upstate) that contains
three non-functional copies of the TCF/LEF binding site
(CCTTTGGCC); and EGFP-N1 encodes an enhanced green-
fluorescent protein used to quantify the efficiency of transfection
when co-transfected with TOP/FOPFlash. N2a-m cells were
transfected using LipofectAMINE 2000 (Invitrogen) according to
the manufacturer’s instructions. For transfection, 600,000 cells
were plated in a 60 mm-culture dish with growth medium and the
day before transfection, the medium was changed to DMEM
without FCS or antibiotics. Co-transfections were performed with
2 ml LipofectAMINE (Invitrogen) and 1 mg of total-DNA (0.75 mg
TOP/FOP plus 0.25 mg EGFP-N1). After transfection, the
medium was changed to DMEM without phenol red or FCS,
supplemented with an antibiotic cocktail. Treatments were started
48 h after transfection to coincide with the maximum expression
levels of the co-transfected proteins.
Other plasmids used for transfection were: empty pcDNA3 as
an internal control; D45 b-catenin, a deleted form of b-catenin
lacking the N-terminal (kindly provided by Dr. R. Moon); and
LEF-1D56 (kindly provided by Dr. R. Grosschedl) that expresses a
form of LEF-1 that is unable to interact with b-catenin.
Primary Cortical Neuron Nucleofection
The TOPFlash plasmid was introduced into cortical neurons by
nucleofection (Basic Nucleofector Kit for Primary Mammalian
Neural cells, Amaxa Bioscience) according to the manufacturer
instructions. A total of 3 mg TOPFlash plus 1 mg GFP was
introduced into 46106 cells, and both luciferase activity and the
efficiency of nucleofection were analyzed after 2 days in culture.
Assay of luciferase activity
After treatment of the TOPFlash transfected N2a-m cells, they
were incubated in 60 mm plate with 1 ml of TEN buffer (40 mM
Figure 9. Gene expression of cDNA/N2a-m and D56LEF-1/N2a-m cells after exposure to estradiol. (A)- Gene expression profile in cDNA/
N2a-m and D56LEF-1/N2a-m stables cell lines. The upper panel reflects the gene induction of some selected genes, in microarray analysis of RNA
collected after a 45 min exposure to estradiol or Wnt3a to detect the early response. Data is expressed as log2R from cDNA/N2a-m cells, that we
denoted as group A, and D56LEF-1/N2a-m cells, that we denoted as group B. The effect of the treatment was compared between the two stable
cell lines (A vs B) (see ‘‘Table 1’’ for a more complete list of the annotated genes). As seen, in the panel we selected some ‘‘putative Wnt-regulated
genes’’, such as Tcf3, Ccnd1 (cyclin D1), GSK3b, Myc and LEF-1, to give some examples of the results in our arrays. We detected changes at the protein
level only in Plg, although there were several genes whose expression varied. For example, the levels of plasminogen RNA were much higher in
group B than group A (ratio AvsB$1), and the expression of LEF-1 was higher in D56LEF-1 due to the mutant expression (ratio AvsB#21). The
western blots below are verifications of these differences at the protein level. Among other proteins that did not change between the groups of cells
were GSK3 b or myc (see western blots on the right). MMP-2 was tested although it did not display a change in its RNA levels and there was no
difference in the total cell extracts. Interestingly, when conditioned medium was prepared, more pro-active MMP-2 (and less active protein) was seen
in D56LEF-1 cells. [Gene_Symbol: Plg (plasminogen), Tcf3, Ccnd1 (cyclin D1), GSK3b, Myc and LEF1]. (B)- Estradiol induction of N-cadherin and cyclin
D2 may be affected by expression of the D56LEF-1 protein. Total cell extracts from cDNA/N2a-m cells (group A) and D56LEF-1/N2a-m cells (group
B) were collected 24 h after estradiol or Wnt3a treatment to analyze several known Wnt or estrogen target genes. As seen in western blots, estradiol
upregulated E-cadherin, N-cadherin and cyclin D2 expression in group A cells. N-cadherin and cyclin D2 were also upregulated by Wnt in group A
cells. In contrast, E-cadherin expression was not Wnt responsive. The regulatory effects of estradiol on E-cadherin, N-cadherin and cyclin D2
expression were lost when D56LEF-1 is expressed, as seen in group B cells. In the case of E-cadherin, the loss of functional LEF-1, which acts as a
known gene repressor, implies higher protein levels even without stimulation. In contrast, levels of actin or cyclin D1 remained unchanged.
doi:10.1371/journal.pone.0005153.g009
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Tris-HCl pH 7.5, 10 mM EDTA, 150 mM NaCl) for 15 min at
RT to detach the cells from the dish. Once the cells had been
collected and pelleted, they were resuspended in 100 ml of lysis-
buffer (100 mM Potassium Phosphate buffer ph 7.8, 1 mM DTT,
0.5% Triton) and incubated on ice for 30 min. The lysate was then
centrifuged at 4uC, 5 min to eliminate aggregates and the
supernatant was transferred to a fresh tube. A fraction of this
supernatant was resolved by electrophoresis to check the cellular
mass and the amount of protein was quantified. The rest of the cell
extract was used to measure the luciferase activity in 200 ml of
luciferase buffer (25 mM Glycyl-glycine, 15 mM MgSO4, 5 mM
ATP, 1 mM DTT, 100 mg/ml BSA) mixed with 20 ml of the cell
extract. The luciferine reaction substrate (Promega) was used at a
concentration of 1 mM (dissolved in sterile water), and we
determined the quantity of luciferase expressed in the cells by
measuring the reaction at 560 nm with a luminometer (Mono-
lightH 2010, Analytical Luminescence Laboratory). The values
obtained correspond to the mean and standard deviation of three
sets of independent experiments. To analyze the induction of b-
catenin co-activator function, the values were normalized to
controls (corresponding to the ratio transfected/non treated cells).
Immunoprecipitation
Inmunoprecipitation assays we carried out on a confluent culture
dish of N2a-m cells that were collected in 0.5 ml of immunopre-
cipitation buffer A (1% Triton X-100, 150 mM NaCl, 10 mM Tris
pH 7.4, 1 mM EDTA pH 8, 1 mM EGTA pH 8, 0.2 mM sodium-
ortho-vanadate, 0.2 mM PMSF, 0,5% NP-40). After incubation on
ice for 30 min, the lysate was centrifuged (160006g at 4uC, 15 min)
to eliminate possible aggregates. The supernatant (100 ml of total
native lysate) was incubated in the following buffer: 2% Triton X-
100, 20 mMTris pH 7.4, 2 mM EDTA pH 8, 2 mM EGTA pH 8,
0.4 mM sodium ortho-vanadate, 0.4 mM PMSF, 1% NP-40) in the
presence of 5 mg of anti-ERa antibody in a total volume of 500 ml.
The mixture was incubated for 1 h at 4uC and subsequently, 10 ul
of Protein A-Agarose solution (Sigma) was added and incubated at
4uC for 30 min with agitation. The agarose beads were recovered
by centrifuging at 160006g for 4 min at 4uC, and the pellet was
washed three times with buffer A and centrifuged (160006g at 4uC).
Finally, the pellet was resuspended in 30 ml of 26 electrophoresis
sample buffer (250 mM Tris pH 6.8, 4% SDS, 10% glycerol,
0.006% bromophenol blue, 2% b-mercaptoethanol), boiled for
10 min and loaded onto an SDS-PAGE gel to be analyzed by
western blotting.
Purification of cortical nuclei
After the dissection of the cortex from 12–16 E18 embryos, the
tissue was homogenized in buffer A (0.32 M sucrose, 10 mM Tris
pH 7.4, 3 mM MgCl2 supplemented with 0.1% Triton-X-100,
protease inhibitors, DTT and PMSF). The homogenate was
centrifuged at 2500 rpm for 10 min at 4uC, the supernatant was
discarded and the pellet was resuspended in buffer A without
Triton, and centrifuged in the same conditions. The pellet
obtained was resuspended in buffer B (the same as buffer A, but
containing 1.9 M sucrose instead of 0.32 M) and homogenized
again. The extract was carefully loaded over buffer C (buffer A,
but with 2 M sucrose) and spun at 12000 rpm for 60 min at 4uC.
The final pellet of the nuclei was resuspended in 50 ml of buffer A,
150 ml of protein extraction buffer (20 mM Tris pH 7.4, 400 mM
NaCl, 0.5 mM EDTA pH 8, 0.5 mM EGTA pH 8, 2 mM
MgCl2) was added and the mix was incubated on ice for 30 min.
To finally obtain the soluble fraction of nuclear proteins, the
extract was centrifuged at 35000 rpm for 30 min at 4uC and the
protein concentration in the extracts was measure using the Lowry
reaction.
Electrophoretic Mobility Shift Assays (EMSA)
To obtain nuclear extracts of N2a-m or cortical neurons, cells were
grown in serum free-DMEM, without phenol red, to 80%
confluence. After washing twice with PBS, 400 ml of EMSA buffer
A was added to each P100 dish (10 mM Tris pH 7.5, 10 mM KCl,
0.1 mM EDTA, 0.1 mM EGTA,1 mM DTT, PMSF, 1 mM
Na3VO4 and protease inhibitor cocktail). Once two confluent
P100 mm dishes were collected in a fresh tube (8 P60 mm in the
case of cortical primary neurons), cells were incubated for 15 min on
ice and then 40 ml of 10% NP-40 was added and vortexed for 20 sec.
The supernatant was centrifuged for 30 sec at 15000 rpm to obtain
the cytoplasm fraction. Once dry-resuspended the pellet containing
the nuclei, 50 ml of EMSA buffer B (20 mM Tris pH 7.5, 400 mM
NaCl, 0.5 mMEDTA, 0.5 mMEGTA, 2 mMMgCl2, 1 mMDTT,
0.5 mM PMSF, 1 mM Na3VO4 and protease inhibitor cocktail) was
added at 4uC with vigorous shaking for 15 min. The samples were
then centrifuged for 30 sec at 15000 rpm and the supernatant
recovered as the nuclear extract. The EMSA assay was performed as
described previously [59]. Protein-primer binding was carried out
with 20 mg of nuclear proteins during 30 min at RT and a similar
amount of each primer (50.000 cpm/ml annealed primer) was added
to the reaction at a concentration of 1 mg/ml (sequence forward: 59-
GTCGCCCTTTGATCTTACC-39, reverse: 59-GTCGGGTAA-
GATCAAAGGG-39, synthetic oligonucleotides from Invitrogen).
When antibodies were used in the EMSA assays, 2 mg of antibody
against TCF-1-X, TCF-3-X and LEF-1-X (from Santa Cruz) and
1 mg of antibody against b-catenin (Transduction Labs) or 0.8 mg of
antibody against ERa (MC-20, Santa Cruz) was added 20 min after
the binding reaction had terminated. Competition experiments were
performed to recognize the specific bands corresponding to the TCF/
LEF-1-DNA complex using TCF/LEF containing the mutated
sequence (sequence forward: 59-GTCGCCCTTTGGCCTTACC-
39, reverse: 59-GTCGGGTAAGGCCAAAGGG-39) and unlabelled-
wild type TCF/LEF sequence at different final concentrations (20 ng
and 100 ng). In all cases, the binding reaction was carried out at a
final concentration of 60–65 mM KCl and in the presence of poly
dIdC (1 mg/ml) and CHAPS (20%). The results of the binding
reaction were analyzed in 4.5% acrylamide/bisacrylamide gels run at
constant 130 V and dried (80uC, 1 h).
Total RNA isolation and RT-PCR quantification
Total RNA was isolated from N2a-m cells from a confluent
P100 mm dish or from 3 P60 mm dishes in the case of cortical
neurons. An additional set of RNA was obtained from N2a-m stable-
transfected with pcDNA3-LEF-1 56 or with empty-pcDNA3, either
untreated or exposed to estradiol or Wnt3a. RNAwas obtained using
TRIzol (GIBCO) and it was finally resuspended in sterile-DEPC
treated water. The RNA concentration was determined by
spectrophotometry at 260 nm, and its integrity was checked using a
Bioanalyzer Chip (Agilent). First strand cDNA synthesis was
performed on 2 mg of RNA and using the reverse primer as the
priming site, hybridized at 37–40uC during 5 min before the
remaining reaction components were added: MMLV Reverse-
Transcriptase, 2.5 mMDTT, and RT-Buffer (GIBCO) with RNAsin
and 10 mM dNTPs. Elongation was performed at 37uC (optimal
temperature for the RT enzyme) and the reaction was finally heated
to 94uC (5 min) to inactivate the RT enzyme. RT-PCR amplification
was performed to analyze cyclin D1, c-myc, actin, b-galactosidase,
actin and GADPH expression using the Master SYBR Green I mix
(Roche) with 2 mM MgCl2 in a lightcycler instrument (Roche
Molecular Biochemicals). PCR was performed under optimal
Estradiol Modulates b-Catenin
PLoS ONE | www.plosone.org 22 April 2009 | Volume 4 | Issue 4 | e5153
conditions for each primer pair. The oligonucleotide sequences and
PCR conditions used were as follows: actin: 94uC-15 s, 57uC-10 s,
72uC-20 s (forward: 59-TGTTTGAGACCTTCAACACC-39; re-
verse: 59-TAGGAGCCAGAGCAGTAATC-39; 600 bp), cyclin
D1: 94uC-15 s, 55uC-10 s, 72uC-20 s (forward: 59-CACAACG-
CACTTTCTTTCCA-39; reverse: 59-GACCAGCCTCTTCCTC-
CAC-39; 164 bp), b-galactosidase: 94uC-15 s, 64uC-5 s, 72uC-
15 s (forward: 59-ATCCTCTGCATGGTCAGGTC-39, reverse: 59-
CGTGGCCTGATTCATTCC-39; 315 bp).
Transgenic mice
The transgenic mice containing the lacZ gene under the control
of three consensus TCF/LEF-binding motifs upstream of the c-fos
promoter have been described previously [21] (strain Tg(Fos-
LacZ)34Efu/J, JAXHMice, The Jackson Laboratory) . The
genotype of the mice was checked using the following primers
and PCR conditions: lacZ rose gene (forward: 59-ATCCTCTG-
CATGGTCAGGTC-39, reverse: 59-CGTGGCCTGATT-
CATTCC-39, 315 bp), endogenous gene (forward: 59-
CAAATGTTGCTTGTCTGGTG-39; reverse: 59-GTCAGTC-
GAGTGCACAGTTT-39, 210 bp). The mouse colony was
maintained in heterozygosis and it was necessary to check each
embryo when used for primary neuronal cultures. Accordingly, a
portion of the cortex was placed in a mixture containing ‘‘Dye
Solution’’ (5 mM K4[Fe(CN)6].3H20, 5 mM K3[Fe(CN)6], 2 mM
MgCl2) and X-Gal (1 mg/ml).
Microarray analysis
Gene expression profiles were generated using Applied
Biosystems Mouse Genome Survey Microarray. Total RNA pools
were cleaned using the RNeasy kit from Qiagen (Hilden,
Germany). Digoxigenin-UTP labeled cDNA probes were gener-
ated and linearly amplified from 1 mg of each RNA pool using
Applied Biosystems Chemiluminescent RT-IVT labeling Kit.
Microarray hybridization, chemiluminescence detection, image
acquisition and analysis were done according to Applied
Biosystems protocols and the 1700 Chemiluminescent Microarray
Analyzer.
Applied Biosystems Expression System software was used to
extract Assay Signal, and Assay Signal to Noise ratio values from
the microarray images. Bad spots flagged by the software were
removed from the analysis. The Assay Signal of the represented
genes was log transformed, loess-normalized (http://www.
bioconductor.org) and further filtered by standard Expression
Array System Signal to Noise threshold (S/N greater than 3 in at
least one sample). The expression profiles of the two control
populations (N2a-m stable-cell lines with or without DLEF-1) were
compared with the corresponding population, treated with either
estradiol or Wnt3a.
Supporting Information
Figure S1 N2a-m cells express both the ERa and ER{lower caes
beta} isoforms of the estrogen receptor and they respond to
estradiol. Immunocytochemistry with anti-ERa and ERb identi-
fied a different cytoplasmic location for the two isoforms in both
cell lines. While ERa presented was diffusely distributed
throughout the cytosol and nucleus, and it accumulated in the
nucleus after the addition of estradiol (A–B). ERb distribution was
more heterogeneous and it could be found in aggregates, diffusely
distributed in the cytosol or in the nucleus(C–D). The addition of
estradiol (B and D) increases the immunoreactivity against two
receptors in the nucleus. Images were analyzed by confocal
microscopy and western blotting confirmed the expression of both
isoforms in total cell extracts from control cells.
Found at: doi:10.1371/journal.pone.0005153.s001 (9.68 MB EPS)
Figure S2 Distribution of b-catenin after exposure of N2a-m
cells to estradiol does not reveal the translocation of b-catenin to
the nucleus. Cell fractions corresponding to the soluble, membrane
and nuclear fractions were analyzed in control and estradiol
treated cells. Neither 30 nor 60 min exposure to estradiol
provoked the nuclear accumulation of b-catenin, statistically
significant. In contrast, recruitment of b-catenin to the membrane
fraction was more evident. We also checked the movement of ERa
as a control of the assay, which clearly accumulated in the nuclear
fraction (see Figure 8).
Found at: doi:10.1371/journal.pone.0005153.s002 (2.36 MB EPS)
Figure S3 N2a-m cells are responsive to Wnt3a protein. (A)-
N2a-m cells respond to Wnt3a (20 ng/ml) with the accumulation
of b-catenin and with a maximal effect observed after 90–
120 minutes. (B)- The transcriptional activity of b-catenin was
analyzed with the TCF-luc reporter. Luciferase activity was
calculated at different concentrations of Wnt3a protein, as
indicated above, and Wnt3a produced a significant increase in
b-catenin/TCF dependent transcription. Asterisk represents P
value from Student’s t-test: * (P#0.05), when compared the two
Wnt concentrations; and ** (P#0.01) when compared with
control.
Found at: doi:10.1371/journal.pone.0005153.s003 (1.61 MB EPS)
Figure S4 Neither ERa nor TCF-3 antibodies modify the
migration of nuclear protein extracts from N2a-m cells exposed to
estradiol or Wnt3a. Nuclear protein extracts were obtained from
control or estradiol/Wnt3a treated cells as indicated in each lane.
The incubation with specific antibodies against ERa or TCF3 did
not produce a higher molecular weight band that migrated more
slowly than that previously identified as a TCF-DNA complex, nor
did they prevent the formation of the complex.
Found at: doi:10.1371/journal.pone.0005153.s004 (2.50 MB EPS)
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